These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 20930868)

  • 1. Management of overactive bladder.
    Gulur DM; Drake MJ
    Nat Rev Urol; 2010 Oct; 7(10):572-82. PubMed ID: 20930868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder.
    Nik-Ahd F; Lenore Ackerman A; Anger J
    Curr Urol Rep; 2018 Sep; 19(11):94. PubMed ID: 30215140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiology of refractory overactive bladder.
    Chen LC; Kuo HC
    Low Urin Tract Symptoms; 2019 Sep; 11(4):177-181. PubMed ID: 30900373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment.
    Peyronnet B; Mironska E; Chapple C; Cardozo L; Oelke M; Dmochowski R; Amarenco G; Gamé X; Kirby R; Van Der Aa F; Cornu JN
    Eur Urol; 2019 Jun; 75(6):988-1000. PubMed ID: 30922690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overactive bladder: diagnosis and management.
    Robinson D; Cardozo L
    Maturitas; 2012 Feb; 71(2):188-93. PubMed ID: 22197347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation and Treatment of Overactive Bladder in Women.
    Raju R; Linder BJ
    Mayo Clin Proc; 2020 Feb; 95(2):370-377. PubMed ID: 32029089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overactive bladder.
    Henderson E; Drake M
    Maturitas; 2010 Jul; 66(3):257-62. PubMed ID: 20399043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric overactive bladder syndrome: pathophysiology and management.
    Franco I
    Paediatr Drugs; 2007; 9(6):379-90. PubMed ID: 18052408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urodynamics in the evaluation of overactive bladder.
    Rovner ES; Goudelocke CM
    Curr Urol Rep; 2010 Sep; 11(5):343-7. PubMed ID: 20585906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Position statement: a clinical approach to the management of adult non-neurogenic overactive bladder.
    Chung E; Lee D; Gani J; Gillman M; Maher C; Brennan J; Johns Putra L; Ahmad L; Chan LL
    Med J Aust; 2018 Jan; 208(1):41-45. PubMed ID: 29320672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overactive bladder symptoms after midurethral sling surgery in women: Risk factors and management.
    Marcelissen T; Van Kerrebroeck P
    Neurourol Urodyn; 2018 Jan; 37(1):83-88. PubMed ID: 28631830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overactive bladder syndrome - management and treatment options.
    Arnold J; McLeod N; Thani-Gasalam R; Rashid P
    Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overactive bladder (OAB): A symptom in search of a disease - Its relationship to specific lower urinary tract symptoms and conditions.
    Van Batavia JP; Combs AJ; Fast AM; Glassberg KI
    J Pediatr Urol; 2017 Jun; 13(3):277.e1-277.e4. PubMed ID: 28527720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of overactive bladder in women].
    Peyronnet B; Rigole H; Damphousse M; Manunta A
    Prog Urol; 2015 Nov; 25(14):877-83. PubMed ID: 26169251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].
    Rechberger T; Kulik-Rechberger B; Miotła P; Wróbel A
    Ginekol Pol; 2014 Mar; 85(3):214-9. PubMed ID: 24783434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology and pharmacotherapy of overactive bladder.
    Yoshida M; Masunaga K; Nagata T; Yono M; Homma Y
    J Pharmacol Sci; 2010; 112(2):128-34. PubMed ID: 20134115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenge of overactive bladder therapy: alternative to antimuscarinic agents.
    Lazzeri M; Spinelli M
    Int Braz J Urol; 2006; 32(6):620-30. PubMed ID: 17201939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overactive bladder treatments in early phase clinical trials.
    Colli E; Digesu GA; Olivieri L
    Expert Opin Investig Drugs; 2007 Jul; 16(7):999-1007. PubMed ID: 17594185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The management of overactive bladder refractory to medical therapy.
    Robinson D; Giarenis I; Cardozo L
    Maturitas; 2013 May; 75(1):101-4. PubMed ID: 23415926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.